Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Endocrinology | Family Medicine
 Disease Category: Diabetes Mellitus, Type 2
Location: United States, CA

Trial Information

TAKEDA EXAMINE trial patients for who have Type II diabetes & ACS coronary artery disease, post angiogram or heart attack. This is a phase 3b study. Currently open for enrollment.

The purpose of this study is to evaluate the cardiovascular outcomes of alogliptin compared with placebo, in addition to standard of care, in patients with type II diabetes mellitus and acute coronary syndrome.

Patient Inclusion Criteria:
In order to participate in this study you need to have a hgA1c level between 6.5-11.0% , and a history of ACS (acute coronary syndrome) that required hospitalization with in 15-90 days prior to randomization.

Patient Exclusion Criteria:

  • Signs of type I diabetes mellitus
  • currently receiving a glucagon- like peptide 1 for glycemic control.
  • Hemodynamically unstable cardiovascular disorder including heart failure
  • Received or is receiving dialysis
  • Patient has human immunodeficiency virus
  • Alcohol or substance abuse

Nasra Hashmi, Clinical Research Specialist
Coastal Multi-Specialty Research
2621 S. Bristol St. Suite 108A
Santa Ana, CA 92704
Phone: 714-754-1684
Email: cmsresearch@coastalheartmedical.com

View Map

Research Center Information: Coastal Multi-Specialty Research

If you would like to learn more about participating in this study, please send an email message using the form below.

Name:
Address:
City:
State:
Country:
Phone:
Email:  
Message:
 

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.